SOPH Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

5.450

Open

5.310

VWAP

5.35

Vol

284.75K

Mkt Cap

456.39M

Low

5.150

Amount

1.52M

EV/EBITDA(TTM)

--

Total Shares

83.90M

EV

445.03M

EV/OCF(TTM)

--

P/S(TTM)

4.51

SOPHiA GENETICS SA is a Switzerland-based company primarily engaged in the healthcare technology industry. The Company’s key product is SOPHiA DDM, which is a cloud-native software-as-a-service (SaaS) platform. The platform analyses multimodal data, including genomics, radiomics, clinical, biological, and digital pathology data, to generate actionable insights for patients with cancer or rare diseases, bringing the power of data-driven medicine to patients across the globe. Additionally, the Company aids BioPharma partners with artificial-intelligence-powered drug discovery, development, and deployment. The Company has offices in Switzerland, France, and the United States and operates worldwide.

Show More

Events Timeline

(ET)

2026-06-16

18:00:00

Sophia Genetics $40M Spot Secondary Re-offered at $4.75

2026-06-16

16:30:00

Sophia Genetics Launches Underwritten Public Offering of Ordinary Shares

2026-06-04 (ET)

2026-06-04

08:10:00

Sophia Genetics Signs MOU with MSK for Joint Venture

2026-05-13 (ET)

2026-05-13

05:10:00

Sophia Genetics Partners with Synnovis for Liquid Biopsy Testing

2026-05-05 (ET)

2026-05-05

06:50:00

SOPHiA GENETICS Reports Q1 Revenue of $21.69M

2026-05-05

06:50:00

Company Adjusts FY26 EBITDA Outlook to $29M-$32M

News

PRnewswire

06-22PRnewswire

SOPHiA GENETICS Shareholders Approve All Proposals

Newsfilter

06-22Newsfilter

SOPHiA GENETICS Shareholders Approve All Proposals

NASDAQ.COM

06-22NASDAQ.COM

SOPHiA GENETICS Closes $57 Million Public Offering

PRnewswire

06-19PRnewswire

SOPHiA GENETICS Closes $57.5 Million Public Offering

Newsfilter

06-19Newsfilter

SOPHiA GENETICS Closes $57.5 Million Public Offering Amid Strong Demand

NASDAQ.COM

06-17NASDAQ.COM

SOPHiA GENETICS Prices Public Offering at $4.75

3 Analyst Rating

Wall Street analysts forecast SOPH stock price to rise

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

7.00

Averages

7.00

High

7.00

Current: 0.000

Low

7.00

Averages

7.00

High

7.00

BTIG

Buy

maintain

$7 -> $8

AI Analysis

2026-04-15

Reason

BTIG

Price Target

$7 -> $8

AI Analysis

2026-04-15

maintain

Buy

Reason

BTIG raised the firm's price target on Sophia Genetics to $8 from $7 and keeps a Buy rating on the shares. After having recently hosted two days of investor meetings with Sophia Genetics' President and soon-to-be CEO Ross Muken, CFO George Cardoza and Head of Strategy Kellen Sanger, the firm reports that management "signaled confidence across the business."

Guggenheim

NULL -> Buy

maintain

$6 -> $7

2026-01-26

Reason

Guggenheim

Price Target

$6 -> $7

2026-01-26

maintain

NULL -> Buy

Reason

Guggenheim raised the firm's price target on Sophia Genetics to $7 from $6 and keeps a Buy rating on the shares. The firm adjusted models, forecasts and targets for a number of its Diagnostics and Life Sciences Tools covered companies to reflect recent updates and selected pre-announcements of preliminary results last week.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for SOPH

Unlock Now

Valuation Metrics

The current forward P/E ratio for Sophia Genetics SA (SOPH.O) is 0.00, compared to its 5-year average forward P/E of -4.65. For a more detailed relative valuation and DCF analysis to assess Sophia Genetics SA's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-4.65

Current PE

0.00

Overvalued PE

-1.92

Undervalued PE

-7.37

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-3.67

Current EV/EBITDA

-5.60

Overvalued EV/EBITDA

-0.58

Undervalued EV/EBITDA

-6.76

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

5.79

Current PS

3.99

Overvalued PS

11.58

Undervalued PS

0.00

Financials

AI Analysis

Annual

Quarterly

Whales Holding SOPH

Generation Investment Management LLP

Trading Trends

People Also Watch

Frequently Asked Questions

What is Sophia Genetics SA (SOPH) stock price today?

The current price of SOPH is 5.44 USD — it has increased 1.87

What is Sophia Genetics SA (SOPH)'s business?

SOPHiA GENETICS SA is a Switzerland-based company primarily engaged in the healthcare technology industry. The Company’s key product is SOPHiA DDM, which is a cloud-native software-as-a-service (SaaS) platform. The platform analyses multimodal data, including genomics, radiomics, clinical, biological, and digital pathology data, to generate actionable insights for patients with cancer or rare diseases, bringing the power of data-driven medicine to patients across the globe. Additionally, the Company aids BioPharma partners with artificial-intelligence-powered drug discovery, development, and deployment. The Company has offices in Switzerland, France, and the United States and operates worldwide.

What is the price predicton of SOPH Stock?

Wall Street analysts forecast SOPH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SOPH is7.00 USD with a low forecast of 7.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Sophia Genetics SA (SOPH)'s revenue for the last quarter?

Sophia Genetics SA revenue for the last quarter amounts to 21.69M USD, increased 21.99

What is Sophia Genetics SA (SOPH)'s earnings per share (EPS) for the last quarter?

Sophia Genetics SA. EPS for the last quarter amounts to -0.27 USD, increased 3.85

How many employees does Sophia Genetics SA (SOPH). have?

Sophia Genetics SA (SOPH) has 415 emplpoyees as of July 08 2026.

What is Sophia Genetics SA (SOPH) market cap?

Today SOPH has the market capitalization of 456.39M USD.